{
  "version": "https://jsonfeed.org/version/1.1",
  "title": "MCAS clinical trials: new and updated - Open Source Medicine Foundation",
  "home_page_url": "https://research.opensourcemed.info/mcas.html",
  "feed_url": "https://research.opensourcemed.info/feeds/mcas.json",
  "description": "ClinicalTrials.gov records for Mast Cell Activation Syndrome (MCAS) that were newly registered or updated, as tracked by the Open Source Medicine Foundation research tracker. The 30 most recently updated trials, newest first.",
  "language": "en",
  "icon": "https://opensourcemed.info/favicon.png",
  "favicon": "https://opensourcemed.info/favicon.png",
  "authors": [
    {
      "name": "Open Source Medicine Foundation",
      "url": "https://opensourcemed.info"
    }
  ],
  "items": [
    {
      "id": "NCT07655375:2026-09-10",
      "url": "https://clinicaltrials.gov/study/NCT07655375",
      "title": "Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut",
      "content_text": "Recruiting · Not applicable · Sample Collection — Study evaluating the effect of UCB8600 on mast cell activation in the human gut: IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no…",
      "summary": "Recruiting · Not applicable · Sample Collection — Study evaluating the effect of UCB8600 on mast cell activation in the human gut: IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (s",
      "tags": [
        "MCAS",
        "Recruiting",
        "Sample Collection"
      ],
      "_osmf": {
        "nct_id": "NCT07655375",
        "status": "RECRUITING",
        "phase": "NA",
        "start_date": "2026-08-18",
        "last_updated": "2026-09-10",
        "agents": [
          "Sample Collection"
        ]
      },
      "date_published": "2026-09-10T08:00:00+00:00",
      "date_modified": "2026-09-10T08:00:00+00:00"
    },
    {
      "id": "NCT05652907:2026-04-21",
      "url": "https://clinicaltrials.gov/study/NCT05652907",
      "title": "Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)",
      "content_text": "Terminated · Phase 2 · Fsd201 — This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.",
      "summary": "Terminated · Phase 2 · Fsd201 — This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.",
      "tags": [
        "MCAS",
        "Terminated",
        "Fsd201"
      ],
      "_osmf": {
        "nct_id": "NCT05652907",
        "status": "TERMINATED",
        "phase": "PHASE2",
        "start_date": "2023-01-19",
        "last_updated": "2026-04-21",
        "agents": [
          "Fsd201"
        ]
      },
      "date_published": "2026-04-21T08:00:00+00:00",
      "date_modified": "2026-04-21T08:00:00+00:00"
    },
    {
      "id": "NCT07454395:2026-03-30",
      "url": "https://clinicaltrials.gov/study/NCT07454395",
      "title": "Is Swimming a More Tolerable Form of Movement for Individuals With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome?",
      "content_text": "Suspended · Not applicable · Swimming, Cycling — Individuals with ME/CFS experience profound exercise intolerance and post-exertional malaise. This remote (app-based) pilot study explores whether light, fully self-paced, swimming may be a tolerable form of movement for people with ME/CFS and related conditions, due to the distinct physiological ef…",
      "summary": "Suspended · Not applicable · Swimming, Cycling — Individuals with ME/CFS experience profound exercise intolerance and post-exertional malaise. This remote (app-based) pilot study explores whether light, fully self-paced, swimming may be a tolerable form of movement for people with ME/CFS and related",
      "tags": [
        "MCAS",
        "Suspended",
        "Swimming",
        "Cycling"
      ],
      "_osmf": {
        "nct_id": "NCT07454395",
        "status": "SUSPENDED",
        "phase": "NA",
        "start_date": "2026-02-20",
        "last_updated": "2026-03-30",
        "agents": [
          "Swimming",
          "Cycling"
        ]
      },
      "date_published": "2026-03-30T08:00:00+00:00",
      "date_modified": "2026-03-30T08:00:00+00:00"
    },
    {
      "id": "NCT05449444:2023-02-06",
      "url": "https://clinicaltrials.gov/study/NCT05449444",
      "title": "Masitinib for the Treatment of Severe Mast Cell Activation Syndrome",
      "content_text": "Unknown · Phase 2 · Masitinib 4.5 Mg/Kg/Day, Best Supportive Care, Masitinib 6.0 Mg/Kg/Day — To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic treatment.",
      "summary": "Unknown · Phase 2 · Masitinib 4.5 Mg/Kg/Day, Best Supportive Care, Masitinib 6.0 Mg/Kg/Day — To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic t",
      "tags": [
        "MCAS",
        "Unknown",
        "Masitinib 4.5 Mg/Kg/Day",
        "Best Supportive Care",
        "Masitinib 6.0 Mg/Kg/Day"
      ],
      "_osmf": {
        "nct_id": "NCT05449444",
        "status": "UNKNOWN",
        "phase": "PHASE2",
        "start_date": "2022-07-01",
        "last_updated": "2023-02-06",
        "agents": [
          "Masitinib 4.5 Mg/Kg/Day",
          "Best Supportive Care",
          "Masitinib 6.0 Mg/Kg/Day"
        ]
      },
      "date_published": "2023-02-06T08:00:00+00:00",
      "date_modified": "2023-02-06T08:00:00+00:00"
    },
    {
      "id": "NCT04978740:2022-12-01",
      "url": "https://clinicaltrials.gov/study/NCT04978740",
      "title": "Ocular and Palpebral Manifestations of Mastocytosis (MOOMA)",
      "content_text": "Completed · Not applicable · Ophthalmological Examination — Mastocytosis is a rare condition characterized by an accumulation of mast cell cells in one or more organs such as the liver, bone marrow, spleen and intestines. Its prevalence in the general population is 1 in 10,000. This pathology is due to the proliferation of a mast cell clone and the excessive…",
      "summary": "Completed · Not applicable · Ophthalmological Examination — Mastocytosis is a rare condition characterized by an accumulation of mast cell cells in one or more organs such as the liver, bone marrow, spleen and intestines. Its prevalence in the general population is 1 in 10,000. This pathology is due",
      "tags": [
        "MCAS",
        "Completed",
        "Ophthalmological Examination"
      ],
      "_osmf": {
        "nct_id": "NCT04978740",
        "status": "COMPLETED",
        "phase": "NA",
        "start_date": "2021-07-30",
        "last_updated": "2022-12-01",
        "agents": [
          "Ophthalmological Examination"
        ]
      },
      "date_published": "2022-12-01T08:00:00+00:00",
      "date_modified": "2022-12-01T08:00:00+00:00"
    }
  ]
}